Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | terminated | Phase 2 | 11 | Telix Pharmaceuticals (Innovations) Pty LtdINDUSTRY | 1 | Jul 10, 2025 | clinicaltrials |
| NCT02849886 | T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.(Side_by_Cide) | terminated | Phase 1 / Phase 2 | 2 | Centre Hospitalier Universitaire de BesanconOTHER |
| 1 |
| Jul 9, 2025 |
| clinicaltrials |
| NCT03432897 | BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects in DNA Repair Genes(337) | terminated | Phase 2 | 1 | Brown UniversityOTHER | 1 | Jul 8, 2025 | clinicaltrials |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | terminated | Phase 2 | 31 | Roswell Park Cancer InstituteOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT03777124 | Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer | terminated | Phase 2 | 25 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04103645 | Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT04455620 | BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors | terminated | Phase 1 / Phase 2 | 49 | BioNTech SEINDUSTRY | 2 | Jul 2, 2025 | clinicaltrials |
| NCT03440437 | A Phase 1/2 Study of FS118 in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 80 | invoX Pharma LimitedINDUSTRY | 2 | Jul 1, 2025 | clinicaltrials |
| NCT04786600 | A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer Using ctDNA: Rapid 1 Trial | terminated | Phase 2 | 6 | University of FloridaOTHER | 1 | Jul 1, 2025 | clinicaltrials |
| NCT05330429 | Study of Magrolimab Given Together With FOLFIRI/Bevacizumab (BEV) in Participants With Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC)(ELEVATE CRC) | terminated | Phase 2 | 77 | Gilead SciencesINDUSTRY | 10 | Jul 1, 2025 | clinicaltrials |
| NCT04530487 | Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults | terminated | Phase 2 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT03737721 | The UNSCARRed Study: UNresctable Squamous Cell Carcinoma Treated With Avelumab and Radical Radiotherapy(UNSCARRed) | terminated | Phase 2 | 8 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT04461418 | Accelerated Checkpoint Therapy for Any Steroid Dependent Patient With Brain Metastases(ACT-FAST) | terminated | Phase 2 | 2 | AHS Cancer Control AlbertaOTHER | 1 | Jun 27, 2025 | clinicaltrials |
| NCT03248492 | A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) | terminated | Phase 2 | 253 | Daiichi SankyoINDUSTRY | 9 | Jun 26, 2025 | clinicaltrials |
| NCT03815942 | VAccination in Early and ADvanced Prostate caNCEr(ADVANCE) | terminated | Phase 1 / Phase 2 | 23 | University of OxfordOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT06370663 | First-line Treatment for Unresectable Locally Advanced Distal Cholangiocarcinoma Combining Radiotherapy and HAIC | terminated | Phase 2 | 1 | Shandong Cancer Hospital and InstituteOTHER | 1 | Jun 25, 2025 | clinicaltrials |
| NCT04102124 | A Study of SHR3680 in Combination With SHR3162 in the Treatment of mCRPC | terminated | Phase 2 | 20 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jun 24, 2025 | clinicaltrials |
| NCT05388851 | Education for Prevention of Melanoma in Hispanic Populations | terminated | Phase 2 | 145 | Mayo ClinicOTHER | 1 | Jun 22, 2025 | clinicaltrials |
| NCT05630937 | Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy | terminated | Phase 1 / Phase 2 | 31 | Nerviano Medical SciencesINDUSTRY | 3 | Jun 19, 2025 | clinicaltrials |
| NCT05634577 | A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical Carcinoma | terminated | Phase 2 | 3 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2025 | clinicaltrials |
| NCT03724084 | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | terminated | Phase 1 / Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2025 | clinicaltrials |
| NCT05161572 | Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer(NeoRacing) | terminated | Phase 2 | 6 | Fudan UniversityOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT03013491 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | terminated | Phase 1 / Phase 2 | 196 | CytomX TherapeuticsINDUSTRY | 6 | Jun 17, 2025 | clinicaltrials |
| NCT05041101 | Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | terminated | Phase 1 / Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05269355 | A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)(SUNRISELMS) | terminated | Phase 2 / Phase 3 | 359 | PTC TherapeuticsINDUSTRY | 12 | Jun 13, 2025 | clinicaltrials |
| NCT05461794 | Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell Carcinoma | terminated | Phase 2 | 96 | BeiGeneINDUSTRY | 1 | Jun 13, 2025 | clinicaltrials |
| NCT05580588 | Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas | terminated | Phase 2 | 14 | Shanghai Pharma Biotherapeutics USA Inc.INDUSTRY | 1 | Jun 13, 2025 | clinicaltrials |
| NCT03325101 | Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma | terminated | Phase 1 / Phase 2 | 7 | Mayo ClinicOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT05712174 | A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer | terminated | Phase 2 | 176 | AHS Cancer Control AlbertaOTHER | 1 | Jun 12, 2025 | clinicaltrials |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | terminated | Phase 1 / Phase 2 | 49 | Formation BiologicsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04019288 | AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | terminated | Phase 1 / Phase 2 | 12 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT04698187 | CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma | terminated | Phase 2 | 44 | Regeneron PharmaceuticalsINDUSTRY | 1 | Jun 11, 2025 | clinicaltrials |
| NCT05243641 | Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients With Abnormal HER-family and c-Met Pathway Activity as Measured by the CELsignia Signaling Analysis Test | terminated | Phase 1 / Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer(neoBREASTIM) | terminated | Phase 1 / Phase 2 | 2 | Institut CurieOTHER | 1 | Jun 11, 2025 | clinicaltrials |
| NCT03292133 | A Study of EGF816 and Gefitinib in TKI-naïve EGFR-mutant Non-Small Cell Lung Cancer | terminated | Phase 2 | 11 | Massachusetts General HospitalOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT03712371 | Study of Chitosan for Pharmacologic Manipulation of AGE Levels in Prostate Cancer Patients | terminated | Phase 1 / Phase 2 | 12 | Medical University of South CarolinaOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT04406272 | VB-111 in Surgically Accessible Recurrent/Progressive GBM | terminated | Phase 2 | 15 | Dana-Farber Cancer InstituteOTHER | 1 | Jun 10, 2025 | clinicaltrials |
| NCT04830124 | Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6(ARTISTRY-6) | terminated | Phase 2 | 173 | Mural Oncology, IncINDUSTRY | 8 | Jun 10, 2025 | clinicaltrials |
| NCT05169684 | A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 2 | 10 | Bristol-Myers SquibbINDUSTRY | 3 | Jun 10, 2025 | clinicaltrials |
| NCT07012330 | Comparing 177Lu-Dotatate/Capecitabine Combination Treatment With 177Lu-Dotatate in Neuroendocrine Tumor Patients | terminated | Phase 2 | 111 | Erasmus Medical CenterOTHER | 0 | Jun 10, 2025 | clinicaltrials |
| NCT05265975 | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL(SWATCH) | terminated | Phase 1 / Phase 2 | 54 | Antengene CorporationINDUSTRY | 1 | Jun 9, 2025 | clinicaltrials |
| NCT01251965 | Phase l/II Study of Ruxolitinib for Acute Leukemia | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT02420717 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT04727151 | TAC T-cells for the Treatment of HER2-positive Solid Tumors(TACTIC-2) | terminated | Phase 1 / Phase 2 | 28 | Triumvira Immunologics, Inc.INDUSTRY | 2 | Jun 8, 2025 | clinicaltrials |
| NCT02446860 | A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic Renal Cell Cancer (ADAPTeR)(ADAPTeR) | terminated | Phase 2 | 15 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT04820023 | Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment | terminated | Phase 1 / Phase 2 | 45 | Bridge Biotherapeutics, Inc.INDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06140407 | Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer | terminated | Phase 2 | 1 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jun 5, 2025 | clinicaltrials |
| NCT01720563 | A Phase II Trial of PG2 in Patients With Advanced Pharyngeal or Laryngeal Squamous Cell Carcinoma Under Concurrent Chemoradiotherapy | terminated | Phase 2 | 17 | PhytoHealth CorporationINDUSTRY | 1 | Jun 4, 2025 | clinicaltrials |
| NCT06790303 | Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2 | terminated | Phase 2 | 8 | GlaxoSmithKlineINDUSTRY | 3 | Jun 4, 2025 | clinicaltrials |
| NCT04251169 | Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression(TATEN) | terminated | Phase 2 | 20 | SOLTI Breast Cancer Research GroupOTHER | 1 | Jun 3, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jul 10, 2025source: clinicaltrials